论文部分内容阅读
目的:研究血清P53抗体在非小细胞肺癌临床病理特征之间的关系,并结合血清中的癌胚抗原、角质蛋白21-1以指导对临床上肺癌复发和转移的分析,用来选择合理的治疗方案。方法:正常组30例,肺良性疾病组10例,肺癌组45例,肺癌全组分别于手术前1天、术后10、30、60和90天时抽取清晨空腹静脉血2ml,23例肺癌病例于手术后120天,15例病例于手术后180天抽取清晨空腹静脉血2ml,肺良性疾病组分别于手术前1天、抽取清晨空腹静脉血2ml。正常组清晨空腹采集静脉血2ml。采用酶联免疫吸附法(ELISA)检测血清P53抗体和角质蛋白21-1,采用荧光酶标免疫法检测血清癌胚抗原。结果:血清P53抗体、CYFRA21-1和CEA在正常人组、良性疾病组、肺癌组术前阳性率的比较三种肿瘤标志物阳性率经X2检验,在肺癌组分别与正常人组和良性病例组有显著性差异(P<0.05),良性病例组和正常人组之间无显著行差异(P>0.05)。并与手术后复发与转移相关。结论:联合检测癌胚抗原、角质蛋白21-1及血清P53抗体水平有助于肺部良恶性疾病的诊断;手术前后动态测定肺癌患者血清P53抗体和角质蛋白21-1的变化规律,有助于判断疗效,监测预后和指导肺癌术后的综合治疗。
Objective: To study the relationship between the serum level of P53 antibody and the clinicopathological characteristics of non-small cell lung cancer (NSCLC), and to combine the serum carcinoembryonic antigen and keratin 21-1 to guide the clinical analysis of relapse and metastasis of lung cancer. Treatment programs. Methods: 30 cases of normal group, 10 cases of lung benign disease group, 45 cases of lung cancer group, all the lung cancer group were 1 day before surgery, 10,30,60 and 90 days after the fasting venous blood samples taken 2ml, 23 cases of lung cancer At 120 days after surgery, 15 cases of early morning fasting venous blood samples were drawn 180 days after surgery, and benign lung disease group was treated with 1 ml of fasting venous blood in one morning before operation. Normal group fasting blood samples collected 2ml. Serum P53 antibody and keratin 21-1 were detected by enzyme-linked immunosorbent assay (ELISA), and serum carcinoembryonic antigen was detected by fluorescence enzyme immunoassay. Results: The positive rate of serum P53 antibody, CYFRA21-1 and CEA in normal group, benign disease group and lung cancer group were compared before and after the positive rate of three tumor markers by X2 test in lung cancer group, normal group and benign group (P <0.05). There was no significant difference between benign and normal controls (P> 0.05). And with recurrence and metastasis after surgery related. Conclusion: The combined detection of carcinoembryonic antigen, keratin 21-1 and serum P53 antibody is helpful for the diagnosis of benign and malignant lung diseases. The changes of serum P53 antibody and keratin 21-1 in patients with lung cancer before and after operation are helpful To determine the efficacy, prognosis and guide the comprehensive treatment of postoperative lung cancer.